Therapeutic Solutions International Inc

NEW
OTCPK:TSOI (USA)  
$ 0.00010 -0.000099 (-99%) 12:08 AM EST
At Loss
Volume:
0
Avg Vol (2M):
0
Trade In:

Business Description

Therapeutic Solutions International Inc
NAICS : 325412 SIC : 2834
ISIN : US8833781011
Description
Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy and traumatic brain injury and Lung Pathology.

Financial Strength

Name Current Vs Industry Vs History

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
12-1 Month Momentum %
-33.33

Liquidity Ratio

Name Current Vs Industry Vs History

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

Name Current Vs Industry Vs History
FCF Margin %
-562.79
OCF Margin %
-562.79

GF Value Rank

Name Current Vs Industry Vs History

Financials (Next Earnings Date:2026-07-06 Est.)

TSOI's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:TSOI

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Therapeutic Solutions International Inc Executives

Details

GF Value™

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.086
EPS (TTM) ($) -
Beta -0.1377
3-Year Sharpe Ratio -0.81
3-Year Sortino Ratio -1.04
Volatility % -
14-Day RSI -
14-Day ATR ($) 0.000007
20-Day SMA ($) 0.0001
12-1 Month Momentum % -33.33
52-Week Range ($) 0.0001 - 0.0002
Shares Outstanding (Mil) 5,122.71

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 0
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Therapeutic Solutions International Inc Filings

Filing Date Document Date Form
No Filing Data

Therapeutic Solutions International Inc Stock Events

Financials Calendars
Event Date Price ($)
Third quarter earnings results for 2026 2026-11-13 In 132 days
Second quarter earnings results for 2026 2026-07-27 In 23 days
First quarter earnings results for 2026 2026-07-06 In 2 days
Third quarter earnings results for 2024 2024-11-20 0.00 (+6.25%)
Second quarter earnings results for 2024 2024-08-19 0.00 (-25.00%)
Show
Entries

Therapeutic Solutions International Inc Frequently Asked Questions

What is Therapeutic Solutions International Inc(TSOI)'s stock price today?
The current price of TSOI is $0.00. The 52 week high of TSOI is $0.00 and 52 week low is $0.00.
When is next earnings date of Therapeutic Solutions International Inc(TSOI)?
The next earnings date of Therapeutic Solutions International Inc(TSOI) is 2026-07-06 Est..
Does Therapeutic Solutions International Inc(TSOI) pay dividends? If so, how much?
Therapeutic Solutions International Inc(TSOI) does not pay dividend.

Guru Commentaries on OTCPK:TSOI

No articles.

Press Release

Subject Date
Therapeutic Solutions International Announces Initiation of JadiCell™ Manufacturing Program to Address Upcoming FDA Phase III Trial and Emergency Use Requests 2021-10-11
Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production 2021-10-04
Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing 2021-09-27
Therapeutic Solutions International Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in COVID-19 Model 2021-09-22
Therapeutic Solutions International Identifies and Files Patent on Combination Effects Between its Nutraceutical QuadraMune™ and Ivermectin in Animal Models of COVID-19 Pathology 2021-09-16
Therapeutic Solutions International Successfully Treats Veteran Navy SEAL Suffering from Chronic Traumatic Encephalopathy with JadiCell™ Adult Stem Cells Under Right to Try Law 2021-09-13
Therapeutic Solutions International Engages Venvalo Group to Oversee JadiCell COVID-19 Phase III Clinical Trial and Emergency Use Authorization (EUA) Process 2021-09-10
Therapeutic Solutions International Signs Memorandum of Understanding with Clinical Stage Immunotherapy Company Eutilogics, Inc. to Explore Augmentation of Synergies between StemVacs-V and TAST 2021-09-07
Therapeutic Solutions International Files Investigational New Drug Application with FDA for Cancer Blood Vessel Targeting Immunotherapy StemVacs-V to Treat Metastatic Breast Cancer 2021-08-30
Therapeutic Solutions International Recruits Internationally Renowned Stem Cell Pioneer Francisco Silva to Scientific Advisory Board 2021-08-26
10/Page

Articles on Therapeutic Solutions International Inc

No articles.

Headlines

See More
  • 1
No news.
  • 1